



**Лекция профессора Кирилла Ларина (Университет
Хьюстона)**

В рамках программы Фонда Дмитрия Зимина «Династия»
«Краткосрочные визиты иностранных ученых в российские
научные центры»

19 сентября 2015г. – 28 сентября 2015 г.

Основы взаимодействия света и биологических тканей








Optical coherence tomography: Noninvasive Sensing of Molecular Diffusion

Kirill V. Larin

Department of Biomedical Engineering
College of Optometry

University of Houston





Molecular Diffusion Studies

Monitoring and quantifying the diffusion of various molecular solutions and drugs in biological tissue

- Speed that drug permeates in tissues
- Effect of solutions' diffusion on tissues
- Distinguishing among normal and abnormal specimens by functional imaging







Ussing Chambers



Disadvantage:
Only *in vitro* studies


fOCT
Molecular Diffusion in Ocular Tissues



An important ability of a chemical compound (agent) to change the tissue scattering properties is based on a number of biophysical processes. The concept of two fluxes – agent into tissue and bulk tissue water out, which may be relatively independent or interacting fluxes defines the dynamic properties of tissue optical clearing and its efficiency


- refractive index matching/mismatching (generally for whole tissue matching an locally mismatching may take place),
- increase of tissue collagen fibers packing density (ordering of scatterers),
- and decrease of tissue thickness.

fOCT
Drug Diffusion in Ocular Tissues





$$\mu_s' = 3.28\pi^2 \rho_s \left(\frac{2\pi}{\lambda} \right)^{0.37} \left(\frac{n_s}{n_{\text{medium}}} - 1 \right)^{2.09}$$


fOCT
Drug Diffusion in Ocular Tissues





$$\mu_s' = 3.28\pi^2 \rho_s \left(\frac{2\pi}{\lambda} \right)^{0.37} \left(\frac{n_s}{n_{\text{medium}} + \delta n_{\text{drug}}} - 1 \right)^{2.09}$$
























Ghosh, Tuchin, Larin: *Optics Letters*, 31, 2006



Permeability Coefficients

Isolated sclera		Rabbit sclera in EYE	
Solution/Drug	PC \pm SD (cm/sec)	Solution/ Drug	PC \pm SD (cm/sec)
Water	$(1.33 \pm 0.28) \times 10^{-5}$ (n=5)	Water	$(4.06 \pm 0.46) \times 10^{-5}$ (n=4)
Glucose (20%)	$(8.64 \pm 1.12) \times 10^{-6}$ (n=14)	Glucose (20%)	$(1.15 \pm 0.01) \times 10^{-5}$ (n=10)
Ciprofloxacin	$(1.41 \pm 0.38) \times 10^{-5}$ (n=3)	Ciprofloxacin	$(3.14 \pm 0.27) \times 10^{-5}$ (n=2)

Larin, Ghosh: *Quantum Electronics*, 12, 2006

Permeability Coefficients

Rabbit Cornea in EYE		Rabbit sclera in EYE	
Solution/Drug	PC \pm SD (cm/sec)	Solution/ Drug	PC \pm SD (cm/sec)
Water	$(1.68 \pm 0.54) \times 10^{-5}$ (n=8)	Water	$(1.33 \pm 0.28) \times 10^{-5}$ (n=5)
Metronidazole	$(1.59 \pm 0.43) \times 10^{-5}$ (n=5)	Metronidazole	$(1.31 \pm 0.29) \times 10^{-5}$ (n=4)
Ciprofloxacin	$(1.85 \pm 0.27) \times 10^{-5}$ (n=7)	Ciprofloxacin	$(1.41 \pm 0.38) \times 10^{-5}$ (n=3)
Dexamethasone	$(2.42 \pm 1.03) \times 10^{-5}$ (n=7)		
Mannitol 20%	$(8.99 \pm 0.72) \times 10^{-6}$ (n=4)	Mannitol 20%	$(6.18 \pm 1.08) \times 10^{-6}$ (n=5)
Mannitol 20%*	$(6.14 \pm 0.61) \times 10^{-5}$ (n=4)		
Glucose 20%	$(1.78 \pm 0.23) \times 10^{-5}$ (n=6)	Glucose 20%	$(8.64 \pm 1.12) \times 10^{-6}$ (n=14)

Ghosh, Tuchin, Larin: *Investigative Ophthalmology & Visual Science*, 48, 2007.

Permeability Coefficients

Rabbit Cornea in EYE		Rabbit sclera in EYE	
Solution/Drug	PC \pm SD (cm/sec)	Solution/ Drug	PC \pm SD (cm/sec)
Water	$(1.13 \pm 0.12) \times 10^{-5}$ (n=5)	Water	$(1.13 \pm 0.20) \times 10^{-5}$ (n=5)
Netronitazone	$(1.58 \pm 0.41) \times 10^{-5}$ (n=5)	Netronitazone	$(1.31 \pm 0.19) \times 10^{-5}$ (n=5)
Ciprofloxacin	$(1.85 \pm 0.77) \times 10^{-5}$ (n=7)	Ciprofloxacin	$(1.41 \pm 0.38) \times 10^{-5}$ (n=5)
Dexamethasone	$(1.51 \pm 1.02) \times 10^{-5}$ (n=7)		
Mannitol 20%	$(8.99 \pm 0.72) \times 10^{-5}$ (n=4)	Mannitol 20%	$(8.18 \pm 1.05) \times 10^{-5}$ (n=5)
Mannitol 20%*	$(6.14 \pm 0.61) \times 10^{-5}$ (n=4)		
Glucose 20%	$(1.78 \pm 0.21) \times 10^{-5}$ (n=5)	Glucose 20%	$(8.54 \pm 1.15) \times 10^{-5}$ (n=5)


Ghosh, Tsuchi, Larin: Investigative Ophthalmology & Visual Science, 48, 2007


foct
Molecular Diffusion in Vasculature


In collaboration with




Joel Morrisett, Ph.D.
Professor
Medicine Athero & Lipo
Baylor College of Medicine










Larin, Ghosn, et al: *Laser Physics Letter*, 4, 2007





Larin, Ghosn, et al: *Laser Physics Letter*, 4, 2007














Doppler OCT (DOCT)


- Moving scatterers change the frequency/phase of the detected signal based on Doppler effect.
- The Doppler signal is obtained as phase difference between consecutive A-lines.
- Velocity is determined by the relation $v = \frac{\Delta\Phi}{2\pi k \tau \cos(\theta)}$


Vitkin et al. "Doppler optical cardiogram gated 2D color flow imaging at 1000 fps and 4D in vivo visualization of embryonic heart at 45 fps on a swept source OCT system"















Optical Angiography (OAG)

- Works on the same principle as that of full length imaging, except that the negative half FT is utilized for imaging velocities instead of structures.
- Let f_s be the modulation frequency introduced moving of reference arm with velocity of v_r . The modified interferogram can be represented by


$$f(k) = \cos[2k(z_r - z_s) + 2k_0(v_r + v_s)t]$$
- When v_s has higher magnitude and opposite direction as that of v_r , then the velocity is reflected at the negative half of FT.
- Modulation frequency can also be introduced offsetting scanning mirrors at the sample arm.



Wang et al. "Three dimensional optical angiography"

Comparing OAG and DOCT


- OAG and DOCT are similar in the respect that, both detect axial velocity.
- DOCT is sensitive to very small velocities in orders of a few microns/sec, where as OAG is insensitive to low velocities including motion of animal being imaged.
- Disadvantage of DOCT is its high phase sensitivity.



OAG DOCT

Wang et al. "Three dimensional optical angiography"

THANK YOU!



Biomedical Optics Laboratory
Department of Biomedical Engineering
University of Houston

Acknowledgements

Collaborators:

• Michael Twa – UH Optometry

• Salavat Aglyamov – UT Austin

• Stas Emelianov – UT Austin

• Fabrice Manns – U. Miami

• Joel Morrisett – BCM

• Juan Granada – WCU

• Valery Tuchin – SSU

• Irina Larina – BCM

• Mary Dickinson – BCM

• Bruce Butler – UTHSC

• Michael Allon – HFC

• JamesMartin– BCM

• Rajesh Miranda– TAMU

• Mohamad Ghosn – Methodist

• Steven Wong – Methodist

• Pradeep Sharma – UH

• Matthew Franciek – UH

• Richard Willson – UH

• Paul Ruchhoeft – UH

• Alexei Sobakin – UW, Madison

• Marlowe Eldridge – UW, Madison

• Raph Pollock - MDACC

Currently Active Funding:

NIH

Rea EY022383

NIDH

R01 HL120940

NIH

U54 HD066348

DOD/NAVSEA

MDN122709

14